Founded in 2005, Beijing HOPE Pharmaceutical Co., Ltd. operates an integrated chemical pharmaceutical platform driven by robust R&D, advanced manufacturing, and global regulatory execution. We provide market-ready solutions tailored to the diverse commercial strategies of our global partners.

Core Business Pillars:

• Technology Transfer & Turn-key Dossiers (FDFs for TT): Validated formulation and process technology packages, comprehensive CTD dossiers, and on-site tech transfer support for fast-track local manufacturing.
• API & Advanced Intermediate Supply: Process optimization, scale-up, and sustainable commercial supply of high-barrier APIs and critical intermediates with US DMF / EU CEP regulatory support.
• Direct Compression & Premix Blends (DC & Premix): High-uniformity, ready-to-press DC blends and customized premixes engineered to streamline local solid-dosage manufacturing and reduce formulation complexities.
• Innovative & Modified Drug Incubation: Advanced discovery and clinical-stage incubation of Class 1 novel chemical entities (First-in-Class / Best-in-Class) and 505(b)(2) / modified-release reformulations.

Global Regulatory & Quality Support:

Supported by our international business arm (HMYA Medical), HOPE actively empowers overseas partners with DMF filings, EU GMP/cGMP-aligned quality dossiers, bioequivalence (BE) study management, and patent non-infringement (design-around) strategies, ensuring launch-ready compliance across regulated and emerging markets.